Clinical Trial

The Role of mGluR5 in CBT-I

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-14; most recent amendment 2026-02-12.
Status change: Enrolling by Invitation → Recruiting 2025-08-22
Trial Details
NCT Number NCT07076342
Lead Sponsor Stony Brook University
Collaborators: National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Conditions Major Depressive Disorder (MDD)
Enrollment 42 participants
Start Date 2025-08-01
Primary Completion 2030-03-31 (estimated)
Study Completion 2030-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-17